New data from Israel-based generics giant Teva Pharmaceutical Industries (NYSE: TEVA) show favorable patient and healthcare ...

More than 92% of schizophrenia patients taking Olanzapine LAI in the Phase 3 SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication 1. These ...

More than 92% of schizophrenia patients taking Olanzapine LAI in the Phase 3 SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication1.

(TEVA), today announced the presentation of a patient and healthcare professional (HCP) attitudes and experiences survey study, complementing the successful Phase 3 Subcutaneous Olanzapine ...

Results from the SOLARIS trial survey showed that over 92% of patients, 87% of nurses, and 72% of physicians expressed satisfaction with TEV-'749’s initiation regimen, dosing schedule, and overall ...

When a murder accused threatened and demanded money from an elderly man, whom he would later fatally assault, he was not ...

Brian Ibe (23), who is charged with the murder of 65-year-old Peter Kennedy at the deceased's home in Moore Park, Newbridge, ...

Axsome Therapeutics said it's dopamine and norepinephrine reuptake inhibitor solriamfetol (Sunosi), approved for excessive ...